Get started
Kymera Therapeutics, Inc.Kymera Therapeutics, Inc.Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsETFs

Chart


Full chart

Latest earnings


Last report date
Feb 26, 2026
Report period
Q4 2025
EPS
−0.97 USD
Revenue
‪2.87 M‬ USD
Earnings call summary

2025 saw major clinical and financial milestones, including strong KT-621 and KT-579 progress, $1.6B year-end cash, and expanded partnerships. KT-621 phase IIb data in AD and asthma expected in 2027, with KT-579 advancing in lupus.

Key stats


Market capitalization
‪6.66 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.68 USD
Net income (FY)
‪−311.35 M‬ USD
Revenue (FY)
‪39.21 M‬ USD
Shares float
‪69.89 M‬
Beta (1Y)
1.99

Employees


Employees (FY)
238
Change (1Y)
+50 +26.60%
Revenue / Employee (1Y)
‪164.75 K‬ USD
Net income / Employee (1Y)
‪−1.31 M‬ USD

About Kymera Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Nello Mainolfi
Website
kymeratx.com
Headquarters
Watertown
Founded
2015
IPO date
Aug 21, 2020
Identifiers
3
ISIN US5015751044
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Check out other big names from the same industry as KYMR.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


VTI
Vanguard Total Stock Market ETF
Weight 0.01%
Market value ‪154.30 M‬
VB
Vanguard Small-Cap ETF
Weight 0.06%
Market value ‪110.49 M‬
IWM
iShares Russell 2000 ETF
Weight 0.16%
Market value ‪110.40 M‬
XBI
State Street SPDR S&P Biotech ETF
Weight 1.04%
Market value ‪84.00 M‬
VBK
Vanguard Small-Cap Growth ETF
Weight 0.15%
Market value ‪61.43 M‬
VXF
Vanguard Extended Market ETF
Weight 0.06%
Market value ‪47.76 M‬
IWO
iShares Russell 2000 Growth Fund
Weight 0.30%
Market value ‪38.54 M‬
IBB
iShares Biotechnology ETF
Weight 0.43%
Market value ‪35.55 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight 0.13%
Market value ‪25.01 M‬
VTWO
Vanguard Russell 2000 ETF
Weight 0.13%
Market value ‪19.52 M‬
DFAS
Dimensional U.S. Small Cap ETF
Weight 0.09%
Market value ‪12.13 M‬

Explore more ETFs 

Frequently asked questions


The current price of KYMR is 81.52 USD — it has decreased by −3.62% in the past 24 hours. Watch Kymera Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kymera Therapeutics, Inc. stocks are traded under the ticker KYMR.
KYMR stock has fallen by −6.27% compared to the previous week, the month change is a 2.88% rise, over the last year Kymera Therapeutics, Inc. has showed a 146.81% increase.
We've gathered analysts' opinions on Kymera Therapeutics, Inc. future price: according to them, KYMR price has a max estimate of 140.00 USD and a min estimate of 91.00 USD. Watch KYMR chart and read a more detailed Kymera Therapeutics, Inc. stock forecast: see what analysts think of Kymera Therapeutics, Inc. and suggest that you do with its stocks.
KYMR reached its all-time high on Dec 8, 2025 with the price of 103.00 USD, and its all-time low was 9.60 USD and was reached on Nov 2, 2023. View more price dynamics on KYMR chart.
See other stocks reaching their highest and lowest prices.
KYMR stock is 3.87% volatile and has beta coefficient of 1.99. Track Kymera Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kymera Therapeutics, Inc. there?
Today Kymera Therapeutics, Inc. has the market capitalization of ‪6.66 B‬, it has decreased by −9.39% over the last week.
Yes, you can track Kymera Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Kymera Therapeutics, Inc. is going to release the next earnings report on Apr 30, 2026. Keep track of upcoming events with our Earnings Calendar.
KYMR earnings for the last quarter are −0.97 USD per share, whereas the estimation was −0.78 USD resulting in a −23.78% surprise. The estimated earnings for the next quarter are −0.87 USD per share. See more details about Kymera Therapeutics, Inc. earnings.
Kymera Therapeutics, Inc. revenue for the last quarter amounts to ‪2.87 M‬ USD, despite the estimated figure of ‪15.05 M‬ USD. In the next quarter, revenue is expected to reach ‪8.01 M‬ USD.
KYMR net income for the last quarter is ‪−86.98 M‬ USD, while the quarter before that showed ‪−82.17 M‬ USD of net income which accounts for 0.00% change. Track more Kymera Therapeutics, Inc. financial stats to get the full picture.
No, KYMR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 12, 2026, the company has 238 employees. See our rating of the largest employees — is Kymera Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kymera Therapeutics, Inc. EBITDA is ‪−337.23 M‬ USD, and current EBITDA margin is −860.04%. See more stats in Kymera Therapeutics, Inc. financial statements.
Like other stocks, KYMR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kymera Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kymera Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kymera Therapeutics, Inc. stock shows the buy signal. See more of Kymera Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.